$4.62 Billion is the total value of Avidity Partners Management LP's 85 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRcall | $337,146,000 | – | 4,062,000 | +100.0% | 7.30% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $124,807,500 | – | 430,000 | +100.0% | 2.70% | – |
| UHS | New | UNIVERSAL HLTH SVCS INCcl b | $116,318,784 | – | 825,600 | +100.0% | 2.52% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $48,422,400 | – | 970,000 | +100.0% | 1.05% | – |
| New | VENTYX BIOSCIENCES INC | $42,135,150 | – | 1,285,000 | +100.0% | 0.91% | – | |
| ICLR | New | ICON PLC | $41,763,750 | – | 215,000 | +100.0% | 0.90% | – |
| DGX | New | QUEST DIAGNOSTICS INC | $40,361,520 | – | 258,000 | +100.0% | 0.87% | – |
| THC | New | TENET HEALTHCARE CORP | $34,997,067 | – | 717,300 | +100.0% | 0.76% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $32,755,297 | – | 9,633,911 | +100.0% | 0.71% | – |
| BNTX | New | BIONTECH SEsponsored ads | $32,357,388 | – | 215,400 | +100.0% | 0.70% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $29,885,093 | – | 1,527,087 | +100.0% | 0.65% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $22,440,000 | – | 204,000 | +100.0% | 0.49% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $21,513,500 | – | 850,000 | +100.0% | 0.47% | – |
| New | BIOHAVEN LTD | $20,708,960 | – | 1,492,000 | +100.0% | 0.45% | – | |
| ISEE | New | IVERIC BIO INC | $17,950,294 | – | 838,407 | +100.0% | 0.39% | – |
| TWST | New | TWIST BIOSCIENCE CORP | $14,547,910 | – | 611,000 | +100.0% | 0.32% | – |
| BCAB | New | BIOATLA INC | $10,395,000 | – | 1,260,000 | +100.0% | 0.22% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,055,949 | – | 104,653 | +100.0% | 0.02% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $879,234 | – | 37,898 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.